A summary of the new GINA strategy: a roadmap to asthma control
…, ML Levy, PM O'Byrne, P Paggiaro… - European …, 2015 - Eur Respiratory Soc
Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and
annually updated a global strategy for asthma management and prevention that has formed …
annually updated a global strategy for asthma management and prevention that has formed …
Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK
The objectives of this article were to estimate the prevalence of asthma control and describe
the characteristics of at least well-controlled (ALWC) versus not well-controlled (NWC) …
the characteristics of at least well-controlled (ALWC) versus not well-controlled (NWC) …
Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.
S Saturni, F Bellini, F Braido, P Paggiaro… - Pulmonary …, 2014 - Elsevier
Randomized Controlled Trials (RCTs) are the “gold standard” for evaluating treatment
outcomes providing information on treatments “efficacy”. They are designed to test a therapeutic …
outcomes providing information on treatments “efficacy”. They are designed to test a therapeutic …
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two …
…, C Hopkins, H Olze, GW Canonica, P Paggiaro… - The Lancet, 2019 - thelancet.com
Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally
have a high symptom burden and poor health-related quality of life, often requiring recurring …
have a high symptom burden and poor health-related quality of life, often requiring recurring …
[HTML][HTML] Tiotropium in asthma poorly controlled with standard combination therapy
…, M Engel, R Dahl, P Paggiaro… - … England Journal of …, 2012 - Mass Medical Soc
… ml in trial 1 (P=0.01) and 154±32 ml in trial 2 (P<0.001). The predose (trough) FEV 1 also
improved in trials 1 and 2 with tiotropium, as compared with placebo: a difference of 88±31 ml (…
improved in trials 1 and 2 with tiotropium, as compared with placebo: a difference of 88±31 ml (…
Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
PL Paggiaro, R Dahle, I Bakran, L Frith, K Hollingworth… - The Lancet, 1998 - thelancet.com
… (p<0·001, p=0·048, respectively), as did clinic FEV 1 (p<0·001), forced vital capacity (p<0·001),
and mid-expiratory flow (p… propionate treatment than with placebo (p=0·004 and p=0·016, …
and mid-expiratory flow (p… propionate treatment than with placebo (p=0·004 and p=0·016, …
Early administration of oral oseltamivir increases the benefits of influenza treatment
FY Aoki, MD Macleod, P Paggiaro… - Journal of …, 2003 - academic.oup.com
Our objective was to evaluate the benefit of early treatment of influenza illness using oral
oseltamivir. This open-label, multicentre international study investigated the relationship …
oseltamivir. This open-label, multicentre international study investigated the relationship …
[HTML][HTML] Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma
…, GW Canonica, P Maestrelli, P Paggiaro… - … England Journal of …, 2007 - Mass Medical Soc
Background Treatment guidelines recommend the regular use of inhaled corticosteroids for
patients with mild persistent asthma. We investigated whether the symptom-driven use of a …
patients with mild persistent asthma. We investigated whether the symptom-driven use of a …
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo …
…, ED Bateman, P Kopecky, P Paggiaro… - The Lancet …, 2016 - thelancet.com
… mL (p=0·0034) in the lebrikizumab 37·5 mg group and 113 mL (p=0·0013) in the lebrikizumab
125 mg group of LAVOLTA I, and 88 mL (p=0·0139) in the 37·5 mg group and 82 mL (p=0·…
125 mg group of LAVOLTA I, and 88 mL (p=0·0139) in the 37·5 mg group and 82 mL (p=0·…
[HTML][HTML] Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease
Methods The median (quartile 1; quartile 3) baseline blood eosinophil count was 181.6 (110.4;
279.8), and the distribution of counts is shown in Figure E1 in the online supplement. The …
279.8), and the distribution of counts is shown in Figure E1 in the online supplement. The …